Tag: GlobeNewswire

Smith+Nephew (LSE: SN, NYSE: SNN) azienda di tecnologia medica, annuncia il lancio commerciale in Europa di CARTIHEAL AGILI-C, l’innovativo impianto per la riparazione della cartilagine. La tecnologia sarà presentata all’International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit, che si terrà a Porto, in Portogallo, dall’8 al 10 ottobre.

Introdotto negli Stati Uniti nel 2024, CARTIHEAL AGILI-C di Smith+Nephew nel panorama della riparazione della cartillagine. Composto da aragonite, un materiale naturale a base di carbonato di calcio, l’impianto agisce come scaffold bifasico favorendo la rigenerazione della cartilagine e dell’osso e contribuendo alleviando il dolore.¹⁻⁵ Questa tecnologia amplia l’accesso alle procedure di riparazione della cartilagine, consentendo di trattare chirurgicamente pazienti che in passato disponevano di opzioni terapeutiche limitate.¹˒⁴˒⁵*

Recentemente pubblicato sull’American Journal of Sports Medicine (AJSM), uno studio multicentrico randomizzato e controllato ha evidenziato la superiorità clinica di CARTIHEAL AGILI-C rispetto allo standard di cura chirurgico. I pazienti trattati con l’impianto hanno registrato punteggi KOOS (Knee injury and Osteoarthritis Outcome Score) complessivamente più elevati durante l’intero periodo di follow-up, fino a 60 mesi dall’intervento.⁵

Click here to play video

Di seguito una traduzione in stile comunicato stampa, mantenendo la struttura e l’enfasi dell’originale:
Inoltre, lo studio ha evidenziato:

• Maggiore sollievo dal dolore: i pazienti trattati con l’impianto CARTIHEAL^◊ AGILI-C^◊ hanno riportato una riduzione significativa del dolore al ginocchio e un miglioramento della qualità di vita nel corso di un periodo di follow-up di 5 anni.¹˒⁴⁻⁶˒*
• Migliori risultati funzionali: i pazienti trattati con l’impianto CARTIHEAL^◊ AGILI-C^◊ hanno riportato miglioramenti superiori nello svolgimento delle attività della vita quotidiana, sportive e ricreative a 2, 4 e 5 anni dal trattamento.¹˒⁴⁻⁶
• Pazienti con e senza osteoartrosi (OA): non sono state riscontrate differenze statisticamente significative negli esiti clinici tra i pazienti con osteoartrosi e quelli senza osteoartrosi trattati con l’impianto CARTIHEAL AGILI-C.⁴˒***

Il Senior Vice President e General Manager Sports Medicine International di Smith+Nephew, ha dichiarato:
«Smith+Nephew è impegnata nello sviluppo di tecnologie innovative in grado di rispondere a importanti bisogni clinici ancora insoddisfatti. Il lancio dell’impianto CARTIHEAL AGILI-C  in Europa mette a disposizione dei chirurghi una soluzione innovativa, supportata da evidenze cliniche, per la riparazione della cartilagine e rafforza il nostro impegno nell’aiutare i pazienti a ottenere risultati nel lungo termine e a tornare a una vita attiva.»

La specialista in Ortopedia e Chirurgia del Ginocchio e dell’Anca presso il Pavia Hospital, ha aggiunto:
«Il trattamento dei difetti cartilaginei e osteocondrali continua a rappresentare una delle sfide più impegnative nell’ambito della medicina ortopedica dello sport. È incoraggiante vedere approcci terapeutici innovativi come l’impianto CARTIHEAL AGILI-C diventare disponibili per un numero sempre maggiore di chirurghi e pazienti in tutto il mondo. Ampliare l’accesso alle nuove tecnologie, insieme alla formazione clinica continua e allo scambio scientifico, contribuisce a migliorare la nostra capacità di affrontare queste condizioni complesse e di ottimizzare la cura dei pazienti.»

L’impianto CARTIHEAL AGILI-C sarà inizialmente commercializzato in Austria, Belgio, Francia, Paesi Bassi, Portogallo, Spagna, Svizzera e Regno Unito, con una successiva estensione ad altri Paesi europei prevista nel prossimo futuro.
Per maggiori informazioni sull’impianto per la riparazione della cartilagine CARTIHEAL AGILI-C di Smith+Nephew, è possibile visitare lo stand dell’azienda durante l’ICRS Summit o consultare la pagina dedicata al prodotto.
 Qui.

– ends –

Media Enquiries
Dave Snyder          +1 (978) 749-1440 
Smith+Nephew      david.snyder@smith-nephew.com

* Over 2-, 4-& 5-year follow-up compared to microfracture or debridement

** Compared to debridement or microfracture

*** Overall KOOS improvements at 48 months; KL 0-1 vs 2-3  

References

1. Altschuler N, Zaslav KR, Di Matteo B, et al. Aragonite-Based Scaffold Versus Microfracture and Debridement for the Treatment of Knee Chondral and Osteochondral Lesions: Results of a Multicenter Randomized Controlled Trial. Am J Sports Med. 2023;51(4):957-967.
2. Kon E, Di Matteo B, Verdonk P, et al. Aragonite-Based Scaffold for the Treatment of Joint Surface Lesions in Mild to Moderate Osteoarthritic Knees: Results of a 2-Year Multicenter Prospective Study. Am J Sports Med. 2021;49(3):588-598.
3. Kon E, Filardo G, Shani J, et al. Osteochondral regeneration with a novel aragonite-hyaluronate biphasic scaffold: up to 12-month follow-up study in a goat model. J Orthop Surg Res. 2015;10:81.
4. Conte P, Anzillotti G, Crawford DC, et al. Differential analysis of the impact of lesions’ location on clinical and radiological outcomes after the implantation of a novel aragonite-based scaffold to treat knee cartilage defects. Int Orthop. 2024;48(12):3117-3126
5. Altschuler N, Zaslav KR, Di Matteo B, et al. Five-Year Follow-up of a Multicenter Randomized Controlled Trial Comparing an Aragonite-Based Scaffold With Microfracture and Debridement for Chondral and Osteochondral Knee Lesions. The American Journal of Sports Medicine. 2026;54(6):1376-1385
6. Kon, E., De Caro, F., Dasa, V., M Scopp, J., Di Matteo, B., Flanigan, D., Shabshin, N., Strickland, S., & Altschuler, N. (2025). Female patients report comparable results to males after the implantation of an aragonite-based scaffold for the treatment of knee chondral and osteochondral defects: a gender-based analysis of a RCT at 4 years’ follow-up. J of Ortho and Traumatology, 26(1), 17.

Informazioni su Smith+Nephew
Smith+Nephew è un’azienda globale di tecnologia medica con un portafoglio focalizzato sulla riparazione, rigenerazione e sostituzione dei tessuti molli e ossa. La sua missione è riportare le persone al pieno benessere del loro corpo e della loro fiducia in sé stesse, usando la tecnologia, questo impegno è racchiuso nel concetto di “Life Unlimited”.
Ogni giorno, i circa 17.000 dipendenti portano avanti questa missione, contribuendo a migliorare la vita dei pazienti grazie all’eccellenza del nostro portafoglio prodotti e allo sviluppo ed applicazione di tecnologie innovative delle nostre tre principali aree di business globali: Ortopedia, Medicina dello Sport & ORL (Otorinolaringoiatria) e Advanced Wound Management.
Fondata nel 1856 a Hull, nel Regno Unito, Smith+Nephew è oggi presente in circa 100 Paesi e nel 2025 ha registrato un fatturato annuo di 6,2 miliardi di dollari.
Smith+Nephew fa parte dell’indice FTSE 100 ed è quotata alla London Stock Exchange (LSE: SN) e alla New York Stock Exchange (NYSE: SNN).
Nel presente comunicato, i termini “Gruppo” e “Smith+Nephew” si riferiscono a Smith & Nephew plc e alle sue società controllate consolidate, salvo ove il contesto richieda diversamente.

Per maggiori informazioni su Smith+Nephew, visitare il sito web aziendale all’indirizzo www.smith-nephew.com e seguici su X, LinkedIn, Instagram o Facebook.

Informazioni sulle prospettive future

Il presente documento può contenere informazioni sulle prospettive future che potrebbero rivelarsi accurate oppure no. Ad esempio, le dichiarazioni relative alla crescita prevista dei ricavi e dei margini di profitto operativo, alle tendenze di mercato e alla pipeline dei prodotti costituiscono informazioni sulle prospettive future. Espressioni quali “mirare”, “pianificare”, “intendere”, “prevedere”, “essere ben posizionati”, “credere”, “stimare”, “aspettarsi”, “puntare a”, “considerare” e termini analoghi sono generalmente utilizzati per identificare informazioni sulle prospettive future.
Le informazioni sulle prospettive future comportano rischi noti e ignoti, incertezze e altri fattori rilevanti che potrebbero determinare risultati effettivi significativamente diversi da quelli espressi o impliciti in tali informazioni. Per Smith+Nephew, tali fattori includono, a titolo esemplificativo: conflitti in Europa e in Medio Oriente; condizioni economiche e finanziarie nei mercati in cui operiamo, in particolare quelle che incidono sugli operatori sanitari, sugli enti pagatori e sui clienti; livelli di prezzo dei dispositivi medici consolidati e innovativi; sviluppi della tecnologia medica; approvazioni normative, decisioni in materia di rimborso o altre azioni governative; difetti di prodotto, richiami o altri problemi relativi ai sistemi di gestione della qualità, oppure il mancato rispetto della relativa normativa; contenziosi relativi a brevetti o ad altre rivendicazioni; rischi legali e finanziari legati alla conformità normativa e le relative attività investigative, correttive o sanzionatorie; interruzioni della catena di fornitura o delle attività operative di Smith+Nephew o dei suoi fornitori; concorrenza per l’acquisizione e la fidelizzazione di personale qualificato; iniziative strategiche, comprese acquisizioni e cessioni, nonché la capacità di svolgere con successo attività di due diligence, valutazione e integrazione delle aziende acquisite; interruzioni derivanti da operazioni straordinarie o da altri cambiamenti apportati ai piani aziendali o all’organizzazione per adeguarsi all’evoluzione del mercato; rapporti con i professionisti sanitari; dipendenza dalle tecnologie informatiche e dalla cybersecurity; interruzioni dovute a calamità naturali, eventi meteorologici e fenomeni legati ai cambiamenti climatici; mutamenti nelle aspettative di clienti e altri stakeholder in materia di sostenibilità; modifiche alla normativa fiscale; effetti della volatilità dei tassi di cambio; nonché numerosi altri fattori che influenzano Smith+Nephew o i mercati in cui opera, inclusi fattori di natura politica, economica, commerciale, competitiva o reputazionale.
Per una descrizione più dettagliata di alcuni di questi fattori, si invita a consultare i documenti depositati da Smith+Nephew presso la U.S. Securities and Exchange Commission (SEC) ai sensi dello U.S. Securities Exchange Act del 1934 e successive modifiche, incluso l’ultimo Annual Report sul Form 20-F, disponibile sul sito della SEC all’indirizzo www.sec.gov.
Qualsiasi informazione sulle prospettive future si basa sulle informazioni disponibili a Smith+Nephew alla data in cui viene formulata. Tutte le informazioni sulle prospettive future, scritte o orali, attribuibili a Smith+Nephew sono soggette alle presenti avvertenze. Smith+Nephew non assume alcun obbligo di aggiornare o rivedere alcuna informazione sulle prospettive future per riflettere eventuali cambiamenti delle circostanze o delle aspettative della Società.

◊ Marchio di Smith+Nephew. Alcuni marchi sono registrati presso lo United States Patent and Trademark Office.

Award builds on a longstanding relationship with CBP and creates a multi-year opportunity to modernize and support the agency’s nationwide simulator network

ORLANDO, Fla., Oct. 06, 2026 (GLOBE NEWSWIRE) — VirTra, Inc. (Nasdaq: VTSI) (“VirTra” or the “Company”), a global leader in immersive, simulation-based training solutions for de-escalation, judgmental use of force and weapons proficiency, today announced that U.S. Customs and Border Protection (CBP) has awarded the Company a sole-source contract to maintain, modernize and support VirTra training systems deployed throughout the agency.

The single-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract carries a five-year ordering period and a maximum potential value of $14 million and represents an important opportunity for VirTra to build on its established federal customer base through modernization, technical support and long-term service. The contract ceiling reflects potential value and does not guarantee orders or revenue.

“This is an exciting milestone for VirTra and a meaningful opportunity to build on our longstanding relationship with CBP,” said John Givens, CEO of VirTra. “It demonstrates how the value of our customer relationships can extend well beyond the initial system deployment. As training requirements and technology evolve, we can help customers modernize their systems, preserve their investment in custom content and continue benefiting from VirTra’s technology and support.”

Through the program, VirTra will assess existing CBP simulators and upgrade them to current supported configurations, beginning in the first quarter of 2027. The scope includes hardware modernization, projection system upgrades, software updates, accessory refreshes, preventative maintenance, annual service visits and remote technical support.

The modernization work will preserve compatibility with CBP’s existing training content while providing access to VirTra’s current supported operating environment. This approach allows the agency to advance its training capabilities while retaining the value of its established simulation infrastructure and custom-developed scenarios.

The contract was awarded on a sole-source basis, reflecting VirTra’s ability to sustain and modernize its installed systems while maintaining compatibility with CBP’s existing training environment.

“Supporting the officers and agents who carry out CBP’s mission is a responsibility we take seriously,” Givens added. “We are proud to help keep their training systems current, reliable and ready for use across an extensive geographic footprint. This program brings together the technology, service and customer commitment that are central to VirTra’s business.”

The program will support CBP training operations across the continental United States, Alaska, Hawaii, Puerto Rico, Guam and other U.S. territories.

For VirTra, the award highlights the long-term business opportunity within its installed base. By supporting customers from initial deployment through modernization and ongoing sustainment, the Company can extend customer relationships and pursue additional business as agencies invest in the continued readiness of their training systems.

About VirTra  
VirTra is a global leader in immersive, simulation-based training solutions for de-escalation, judgmental use of force and weapons proficiency. Serving military, law enforcement, military, educational, and commercial organizations, VirTra combines advanced technology, realistic scenarios and proprietary training tools to help users improve decision-making, strengthen readiness and perform more effectively under pressure. Since 1993, VirTra has been committed to its mission of saving lives by preparing professionals for the complex, high-stakes situations they may face in the real world.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” provisions of those sections. Forward-looking statements are generally identified by words such as “anticipates,” “believes,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “should,” “could,” “predicts,” “potential,” “continue,” “would,” and similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements in this release include, but are not limited to, statements regarding the Company’s ability to support customer engagement, program activity, partner collaboration, future operational needs, domestic manufacturing capabilities, national readiness, and the continued advancement and adoption of its simulation training solutions across military and law enforcement markets. Actual results may differ materially from those expressed or implied by these forward-looking statements due to various risks and uncertainties, including those described in the Company’s filings with the Securities and Exchange Commission (“SEC”). These forward-looking statements speak only as of the date of this release. VirTra undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this release, except as required by law.

Investor Relations Contact: 
Gateway Group, Inc. 
VTSI@gateway-grp.com
949-574-3860 

Company announcement no. 38 – 26
06 October 2026

Transactions in connection with share buy-back program

On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 3 – 26. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules.

The purposes of the share buy-back programme are to meet obligations relating to acquisition of minority shareholders’ shares in NTG subsidiaries under the “Ring-the-Bell” concept, cover obligations arising under share-based incentive programmes, and potentially for other purposes such as payment in relation to potential M&A transactions.

During the period, NTG will purchase its own shares for an aggregate maximum amount of DKK 200,000,000, up to 1,250,000 shares (nominally DKK 25,000,000), corresponding to 5.52% of the current share capital of NTG.

The share buy-back programme will run from 5 March 2026 to 9 November 2026 at the latest, both days inclusive.

The following transactions have been made under the share buy-back program:

	Number of shares	Average purchase price (DKK)	Transaction value (DKK)
Accumulated, latest announcement	769,120		168,999,051
29 September 2026	3,500	284.0	994,000
30 September 2026	1,500	285.5	428,220
01 October 2026	1,034	277.8	287,228
02 October 2026	500	288.2	144,120
05 October 2026	768	289.1	222,005
Accumulated under the program	776,422		171,074,623

With the transactions stated above, NTG owns a total of 1,069,247 treasury shares, corresponding to 4.72% of the current share capital of NTG.

Details of each transaction are included as appendix.

Additional information

For additional information, please contact:

Investor relations & Press: Sebastian Rosborg Head of Investor Relations  & External communications

+45 42 12 80 99 sebastian.rosborg@ntg.com ir@ntg.com | press@ntg.com

Attachments

• Appendix_Company announcement no 38_2026
• Company announcement no 38_2026

Smith+Nephew (LSE: SN, NYSE: SNN), compañía global de tecnología médica, anuncia hoy que su innovador implante de reparación de cartílago CARTIHEAL AGILI-C ya está disponible para su comercialización en Europa. El implante CARTIHEAL ocupará un lugar destacado en el Congreso de la Sociedad International de Regeneración de Cartílago & Preservación Articular (ICRS), que se celebrará en Oporto (Portugal) del 8 al 10 de octubre.

Introducido por Smith+Nephew en Estados Unidos durante 2024, el implante CARTIHEAL está transformando rápidamente el panorama de la reparación del cartílago. Compuesto por aragonito, una forma natural de carbonato cálcico que actúa como un soporte bifásico, el implante permite reparar el cartílago, restaurar el hueso y aliviar el dolor.¹⁻⁵ Gracias a estas características únicas, los cirujanos pueden tratar quirúrgicamente a pacientes que anteriormente no tenían acceso a procedimientos de reparación cartilaginosa.¹˒⁴˒⁵

Recientemente se han publicado en el American Journal of Sports Medicine (AJSM) los resultados de un ensayo clínico multicéntrico y aleatorizado que demuestran la superioridad clínica del implante CARTIHEAL. El estudio concluyó que el implante de reparación de cartílago CARTIHEAL AGILI-C obtuvo mejores resultados globales en la escala KOOS (Knee injury and Osteoarthritis Outcome Score) en comparación con el tratamiento quirúrgico estándar**, en todos los puntos temporales evaluados hasta los 60 meses de seguimiento.⁵

Click here to play video

Además, el estudio también demostró:

• Mayor alivio del dolor: los pacientes tratados con el implante CARTIHEAL AGILI-C presentaron una reducción significativamente superior del dolor de rodilla y una mejor calidad de vida durante un periodo de seguimiento de 5 años.¹˒⁴⁻⁶
• Mejoría funcional superior: los pacientes tratados con el implante CARTIHEAL mostraron mejoras significativamente mayores en actividades de la vida diaria, deporte y actividades recreativas a los 2, 4 y 5 años de seguimiento.¹˒⁴⁻⁶
• Pacientes con y sin artrosis: no se observaron diferencias estadísticamente significativas en los resultados clínicos entre pacientes con artrosis y sin artrosis tratados con el implante CARTIHEAL.⁴

Joaquín Lasso, Vicepresidente Senior y Director General Internacional de Medicina Deportiva de Smith+Nephew, comentó:

“En Smith+Nephew estamos comprometidos con el desarrollo de tecnologías que respondan a necesidades clínicas relevantes aún no cubiertas. El lanzamiento del implante CARTIHEAL en Europa ofrece a los cirujanos una solución innovadora respaldada por evidencia científica para la reparación del cartílago y refuerza nuestro objetivo de ayudar a los pacientes a lograr mejores resultados a largo plazo y volver a una vida activa.”

Por su parte, la Dra. Francesca de Caro, especialista en Cirugía Ortopédica, de Rodilla y Cadera del Hospital Pavia (Italia), señaló:

“El tratamiento de los defectos condrales y osteocondrales sigue siendo uno de los mayores desafíos en la medicina deportiva ortopédica. Es alentador ver cómo enfoques terapéuticos innovadores como el implante CARTIHEAL AGILI-C están cada vez más disponibles para cirujanos y pacientes de todo el mundo. Ampliar el acceso a nuevas tecnologías, junto con la formación clínica y el intercambio científico continuos, contribuye a mejorar nuestra capacidad para abordar estas complejas patologías y optimizar la atención a los pacientes.”

El implante CARTIHEAL se lanzará inicialmente en Austria, Bélgica, Francia, Alemania, Irlanda, Italia, Luxemburgo, Países Bajos, Portugal, España, Suiza y Reino Unido, con una expansión prevista a otros países poco después.

Para obtener más información sobre el implante de reparación de cartílago CARTIHEAL AGILI-C, visite el stand de Smith+Nephew durante el congreso ICRS o consulte la página del producto aquí.

Fin.

Media Enquiries
Dave Snyder         +1 (978) 749-1440 
Smith+Nephew      david.snyder@smith-nephew.com

* Over 2-, 4-& 5-year follow-up compared to microfracture or debridement

** Compared to debridement or microfracture

*** Overall KOOS improvements at 48 months; KL 0-1 vs 2-3  

Referencias

1. Altschuler N, Zaslav KR, Di Matteo B, et al. Aragonite-Based Scaffold Versus Microfracture and Debridement for the Treatment of Knee Chondral and Osteochondral Lesions: Results of a Multicenter Randomized Controlled Trial. Am J Sports Med. 2023;51(4):957-967.
2. Kon E, Di Matteo B, Verdonk P, et al. Aragonite-Based Scaffold for the Treatment of Joint Surface Lesions in Mild to Moderate Osteoarthritic Knees: Results of a 2-Year Multicenter Prospective Study. Am J Sports Med. 2021;49(3):588-598.
3. Kon E, Filardo G, Shani J, et al. Osteochondral regeneration with a novel aragonite-hyaluronate biphasic scaffold: up to 12-month follow-up study in a goat model. J Orthop Surg Res. 2015;10:81.
4. Conte P, Anzillotti G, Crawford DC, et al. Differential analysis of the impact of lesions’ location on clinical and radiological outcomes after the implantation of a novel aragonite-based scaffold to treat knee cartilage defects. Int Orthop. 2024;48(12):3117-3126
5. Altschuler N, Zaslav KR, Di Matteo B, et al. Five-Year Follow-up of a Multicenter Randomized Controlled Trial Comparing an Aragonite-Based Scaffold With Microfracture and Debridement for Chondral and Osteochondral Knee Lesions. The American Journal of Sports Medicine. 2026;54(6):1376-1385 Kon, E., De Caro, F., Dasa, V., M Scopp, J., Di Matteo, B., Flanigan, D., Shabshin, N., Strickland, S., & Altschuler, N. (2025). Female patients report comparable results to males after the implantation of an aragonite-based scaffold for the treatment of knee chondral and osteochondral defects: a gender-based analysis of a RCT at 4 years’ follow-up. J of Ortho and Traumatology, 26(1), 17.

Acerca de Smith+Nephew
Smith+Nephew es una compañía de tecnología médica con un amplio portafolio de soluciones centradas en la reparación, regeneración y sustitución de tejidos blandos y estructuras óseas. Nuestra razón de ser es ayudar a restaurar la funcionalidad física y la confianza de las personas mediante el uso de la tecnología para eliminar las limitaciones a la hora de vivir plenamente. A este propósito lo llamamos “Life Unlimited”.
Nuestros 17.000 empleados trabajan cada día para cumplir esta misión, mejorando la vida de los pacientes a través de la excelencia de nuestra cartera de productos y del desarrollo y aplicación de nuevas tecnologías en nuestras tres áreas globales de negocio:

• Ortopedia
• Medicina Deportiva y ORL (Otorrinolaringología)
• Tratamiento Avanzado de Heridas

Fundada en Hull (Reino Unido) en 1856, Smith+Nephew opera actualmente en alrededor de 100 países y alcanzó unas ventas anuales de 6.200 millones de dólares en 2025.
Smith+Nephew forma parte del índice FTSE 100 y cotiza en la Bolsa de Londres (LSE: SN) y en la Bolsa de Nueva York (NYSE: SNN). Los términos “Grupo” y “Smith+Nephew” se utilizan para referirse a Smith & Nephew plc y a sus filiales consolidadas, salvo que el contexto indique lo contrario.

Para obtener más información sobre Smith+Nephew, visite www.smith-nephew.com y síganos en X, LinkedIn, Instagram o Facebook.

Declaraciones Prospectivas
Este documento puede contener declaraciones prospectivas que pueden o no resultar exactas. Por ejemplo, las declaraciones relativas al crecimiento esperado de los ingresos, los márgenes de beneficio operativo, las tendencias del mercado y nuestra cartera de productos en desarrollo constituyen declaraciones prospectivas. Expresiones como “objetivo”, “plan”, “intención”, “anticipar”, “bien posicionados”, “creer”, “estimar”, “esperar”, “meta” o “considerar”, así como otras similares, tienen generalmente como finalidad identificar este tipo de declaraciones.
Las declaraciones prospectivas implican riesgos conocidos y desconocidos, incertidumbres y otros factores relevantes que podrían provocar que los resultados reales difieran de forma significativa de los expresados o implícitos en dichas declaraciones. En el caso de Smith+Nephew, estos factores incluyen, entre otros: los conflictos en Europa y Oriente Medio; las condiciones económicas y financieras de los mercados en los que operamos, especialmente aquellas que afectan a proveedores sanitarios, financiadores y clientes; los niveles de precios de los productos sanitarios establecidos e innovadores; los avances en tecnología médica; las aprobaciones regulatorias, decisiones de reembolso u otras actuaciones gubernamentales; defectos de producto, retiradas del mercado u otros problemas relacionados con los sistemas de gestión de calidad o el incumplimiento de la normativa aplicable; litigios relacionados con patentes u otras reclamaciones; riesgos de cumplimiento legal y financiero, así como investigaciones, medidas correctivas o acciones regulatorias asociadas; interrupciones en nuestra cadena de suministro o nuestras operaciones, o en las de nuestros proveedores; la competencia por personal cualificado; acciones estratégicas, incluidas adquisiciones y desinversiones, así como nuestra capacidad para realizar los procesos de diligencia debida, valoración e integración de los negocios adquiridos; posibles disrupciones derivadas de transacciones u otros cambios en nuestros planes de negocio u organización para adaptarnos a la evolución del mercado; las relaciones con los profesionales sanitarios; la dependencia de las tecnologías de la información y la ciberseguridad; interrupciones derivadas de desastres naturales, fenómenos meteorológicos o eventos relacionados con el cambio climático; cambios en las expectativas de sostenibilidad de clientes y otros grupos de interés; modificaciones en la normativa fiscal; los efectos de la volatilidad de los tipos de cambio; y otras muchas cuestiones que afectan a nuestra compañía o a nuestros mercados, incluidas aquellas de naturaleza política, económica, empresarial, competitiva o reputacional.
Para obtener una descripción más detallada de algunos de estos factores, consulte la documentación presentada por Smith+Nephew ante la Comisión de Bolsa y Valores de Estados Unidos (SEC) de conformidad con la Securities Exchange Act de 1934, según sus modificaciones, incluido el Informe Anual más reciente de Smith+Nephew en el Formulario 20-F, disponible en www.sec.gov.
Cualquier declaración prospectiva se basa en la información disponible para Smith+Nephew en la fecha en que se realiza dicha declaración. Todas las declaraciones prospectivas, ya sean escritas u orales, atribuibles a Smith+Nephew están sujetas a esta advertencia. Smith+Nephew no asume obligación alguna de actualizar o revisar ninguna declaración prospectiva para reflejar cambios en las circunstancias o en las expectativas de la compañía.

^◊ Marca registrada de Smith+Nephew. Algunas marcas están registradas en la Oficina de Patentes y Marcas de los Estados Unidos (USPTO).ç

DIRIGIDO EXCLUSIVAMENTE A PROFESIONALES SANITARIOS
PRODUCTO CONFORME A LA NORMATIVA APLICABLE A PRODUCTOS SANITARIOS

Admiral Markets AS (registry code 10932555) is organizing an additional buyback offer for its outstanding Tier 2 bonds issued on 28 December 2017 (ISIN EE3300111251, nominal value EUR 100 per bond, maturity date 28 December 2027, hereinafter the “Bond”) during the period from 8 October 2026 to 29 October 2026 at a price of EUR 103,78 per bond. The value date of the Bond transaction is 2 November 2026 or a date close thereto. 

The buyback offer is directed solely to the current bond investors of Admiral Markets AS (hereinafter the “Investor”). 

Admiral Markets AS hereby announces an additional buyback offer for its subordinated Bonds. The objective of Admiral Markets AS is to provide all remaining Investors with an opportunity to sell their Bonds to Admiral Markets AS prior to the termination of the listing and trading of the Bonds on the Nasdaq Tallinn Stock Exchange. 

On 29 September 2026, the Listing and Surveillance Committee of Nasdaq Tallinn AS decided to approve the termination of the listing and trading of the Bonds subject to, among other conditions, Admiral Markets AS conducting an additional buyback offer before the termination of the listing. Under the conditions established by Nasdaq Tallinn AS, all Investors must be provided with an opportunity to sell their Bonds to Admiral Markets AS for their nominal value, together with accrued interest as of the value date and a premium of EUR 1 per Bond. 

The buyback will take place under the following conditions: 

• the purchase price is EUR 103,78 per Bond, consisting of the Bond’s nominal value (EUR 100), a premium (EUR 1), and accrued interest as of the value date (EUR 2,78); and  

• the Bonds must not be encumbered by third-party rights. 

All Investors may offer their Bonds to Admiral Markets AS for repurchase on equal terms. 

To participate in the buyback, the Investor must submit an off-exchange sell order during the submission period through their bank (custodian of the securities account opened with Nasdaq CSD SE) within the relevant corporate action for the Admiral Markets AS Bond, indicating in the sell order the number of Bonds or other information required in the application that the Investor wishes to sell back to Admiral Markets AS under the terms published in this notice. 

The Investor may use any method offered by their custodian for submitting sell orders (e.g. physically at the customer service office of the custodian, online, or otherwise). An Investor’s sell offer is deemed submitted once Nasdaq CSD receives a duly completed sell order from the Investor’s custodian. The Investor has the right to amend or cancel their sell order at any time until the end of the sell order submission period. 

To do so, the Investor must contact the custodian through whom the relevant order was made and complete the procedures required by the custodian for amendment or cancellation of the order. Upon submission of a sell order, the custodian will block the corresponding amount of securities in the Investor’s securities account. The Investor shall bear all costs and fees related to the submission, cancellation, or amendment of the sell order. 

By submitting a sell order, each Investor: 

• agrees that this notice shall not be considered an offer to conclude a bond repurchase agreement within the meaning of Section 16(1) of the Law of Obligations Act or in any other sense, and that submission of a sell order does not in itself create a binding repurchase agreement between Admiral Markets AS and the Investor; 
• confirms that the number of Bonds indicated in the sell order is the number of Bonds the Investor wishes to sell to Admiral Markets AS under the terms of the buyback offer; 
• authorizes the custodian of the Investor’s securities account or Nasdaq CSD to amend the information contained in the Investor’s sell order where necessary for the settlement of the repurchase transaction; 
• confirms that the Bonds owned by the Investor are not encumbered by third-party rights; 
• confirms that they: (i) have reviewed the contents of this offer notice; (ii) are aware that the listing and trading of the Bonds on the Nasdaq Tallinn Stock Exchange will be terminated following completion and settlement of the buyback offer in accordance with the decision of Nasdaq Tallinn AS; and (iii) understand the consequences of selling or not selling the Bonds under this offer; and 
• consents to the exchange of their personal data between custodians, Nasdaq CSD and Admiral Markets AS both during and after the sell order submission period for the purpose of participation in the buyback. 

Summary of Key Terms of the Offer 

The offer period during which Bonds may be sold back to Admiral Markets AS begins on 8 October 2026 at 10:00 and ends on 29 October 2026 at 16:00 (Estonian time). 

The repurchase price for each Bond is EUR 103,78 (of which EUR 100 is the nominal value of the Bond and EUR 1 is the premium, plus accrued interest up to the value date in the amount of EUR 2,78). Only whole-number Bonds may be offered for repurchase. 

An Investor wishing to submit a repurchase order must contact the custodian of their securities account opened in the Estonian Register of Securities. 

IMPORTANT DATES

The timetable below sets out the key dates related to the offer: 

• 8 October 2026 – Start of the offer period (start of submission of offers to custodians) 
• 29 October 2026 – End of the offer period (end of submission of offers to custodians) 
• 30 October 2026 or a date close thereto – Admiral Markets AS publishes the results of the buyback offer 
• 2 November 2026 or a date close thereto – Settlement date, i.e. the date of transfer of Bond(s) and payment 
• 3 November 2026 or first possible trading day following completion of settlement – Termination of the listing and trading of the Bonds on the Nasdaq Tallinn Stock Exchange 

For additional information, please contact: 

Anton Tikhomirov 
Member of the Management Board 

Admiral Markets AS 
+37251961122 

Anton.Tikhomirov@admiralmarkets.com 

Admiral Markets AS (registry code 10932555) is organizing an additional buyback offer for its outstanding Tier 2 bonds issued on 28 December 2017 (ISIN EE3300111251, nominal value EUR 100 per bond, maturity date 28 December 2027, hereinafter the “Bond”) during the period from 8 October 2026 to 29 October 2026 at a price of EUR 103,78 per bond. The value date of the Bond transaction is 2 November 2026 or a date close thereto. 

The buyback offer is directed solely to the current bond investors of Admiral Markets AS (hereinafter the “Investor”). 

Admiral Markets AS hereby announces an additional buyback offer for its subordinated Bonds. The objective of Admiral Markets AS is to provide all remaining Investors with an opportunity to sell their Bonds to Admiral Markets AS prior to the termination of the listing and trading of the Bonds on the Nasdaq Tallinn Stock Exchange. 

On 29 September 2026, the Listing and Surveillance Committee of Nasdaq Tallinn AS decided to approve the termination of the listing and trading of the Bonds subject to, among other conditions, Admiral Markets AS conducting an additional buyback offer before the termination of the listing. Under the conditions established by Nasdaq Tallinn AS, all Investors must be provided with an opportunity to sell their Bonds to Admiral Markets AS for their nominal value, together with accrued interest as of the value date and a premium of EUR 1 per Bond. 

The buyback will take place under the following conditions: 

• the purchase price is EUR 103,78 per Bond, consisting of the Bond’s nominal value (EUR 100), a premium (EUR 1), and accrued interest as of the value date (EUR 2,78); and  

• the Bonds must not be encumbered by third-party rights. 

All Investors may offer their Bonds to Admiral Markets AS for repurchase on equal terms. 

To participate in the buyback, the Investor must submit an off-exchange sell order during the submission period through their bank (custodian of the securities account opened with Nasdaq CSD SE) within the relevant corporate action for the Admiral Markets AS Bond, indicating in the sell order the number of Bonds or other information required in the application that the Investor wishes to sell back to Admiral Markets AS under the terms published in this notice. 

The Investor may use any method offered by their custodian for submitting sell orders (e.g. physically at the customer service office of the custodian, online, or otherwise). An Investor’s sell offer is deemed submitted once Nasdaq CSD receives a duly completed sell order from the Investor’s custodian. The Investor has the right to amend or cancel their sell order at any time until the end of the sell order submission period. 

To do so, the Investor must contact the custodian through whom the relevant order was made and complete the procedures required by the custodian for amendment or cancellation of the order. Upon submission of a sell order, the custodian will block the corresponding amount of securities in the Investor’s securities account. The Investor shall bear all costs and fees related to the submission, cancellation, or amendment of the sell order. 

By submitting a sell order, each Investor: 

• agrees that this notice shall not be considered an offer to conclude a bond repurchase agreement within the meaning of Section 16(1) of the Law of Obligations Act or in any other sense, and that submission of a sell order does not in itself create a binding repurchase agreement between Admiral Markets AS and the Investor; 
• confirms that the number of Bonds indicated in the sell order is the number of Bonds the Investor wishes to sell to Admiral Markets AS under the terms of the buyback offer; 
• authorizes the custodian of the Investor’s securities account or Nasdaq CSD to amend the information contained in the Investor’s sell order where necessary for the settlement of the repurchase transaction; 
• confirms that the Bonds owned by the Investor are not encumbered by third-party rights; 
• confirms that they: (i) have reviewed the contents of this offer notice; (ii) are aware that the listing and trading of the Bonds on the Nasdaq Tallinn Stock Exchange will be terminated following completion and settlement of the buyback offer in accordance with the decision of Nasdaq Tallinn AS; and (iii) understand the consequences of selling or not selling the Bonds under this offer; and 
• consents to the exchange of their personal data between custodians, Nasdaq CSD and Admiral Markets AS both during and after the sell order submission period for the purpose of participation in the buyback. 

Summary of Key Terms of the Offer 

The offer period during which Bonds may be sold back to Admiral Markets AS begins on 8 October 2026 at 10:00 and ends on 29 October 2026 at 16:00 (Estonian time). 

The repurchase price for each Bond is EUR 103,78 (of which EUR 100 is the nominal value of the Bond and EUR 1 is the premium, plus accrued interest up to the value date in the amount of EUR 2,78). Only whole-number Bonds may be offered for repurchase. 

An Investor wishing to submit a repurchase order must contact the custodian of their securities account opened in the Estonian Register of Securities. 

IMPORTANT DATES

The timetable below sets out the key dates related to the offer: 

• 8 October 2026 – Start of the offer period (start of submission of offers to custodians) 
• 29 October 2026 – End of the offer period (end of submission of offers to custodians) 
• 30 October 2026 or a date close thereto – Admiral Markets AS publishes the results of the buyback offer 
• 2 November 2026 or a date close thereto – Settlement date, i.e. the date of transfer of Bond(s) and payment 
• 3 November 2026 or first possible trading day following completion of settlement – Termination of the listing and trading of the Bonds on the Nasdaq Tallinn Stock Exchange 

For additional information, please contact: 

Anton Tikhomirov 
Member of the Management Board 

Admiral Markets AS 
+37251961122 

Anton.Tikhomirov@admiralmarkets.com 

French limited company (Société anonyme)
with registered capital of 106,529,962.80 euros
Registered office: 14, rue Royale, 75008 Paris
632 012 100 R.C.S. Paris
Legal Entity Identifier: 529900JI1GG6F7RKVI53

Disclosure of total number of voting rights and number of shares
in the capital at September 30, 2026

Pursuant to article L-233-8 II of the French “Code de Commerce” and
223-16 of the AMF’s General Regulations:

Total number of shares	532,649,827
Number of real voting rights (excluding treasury shares)	532,649,827
Theoretical number of voting rights (including treasury shares*) (*) pursuant to article 223-11 of the AMF’s General Regulations	532,649,827

About L’Oréal

For over 115 years, L’Oréal, the world’s leading beauty player, has devoted itself to one thing only: fulfilling the beauty aspirations of consumers around the world. Our purpose, to create the beauty that moves the world, defines our approach to beauty as essential, inclusive, ethical, generous and committed to social and environmental sustainability. With our broad portfolio of 40 international brands and ambitious sustainability commitments in our L’Oréal for the Future programme, we offer each and every person around the world the best in terms of quality, efficacy, safety, sincerity and responsibility, while celebrating beauty in its infinite plurality.

With more than 95,000 committed employees, a balanced geographical footprint and sales across all distribution networks (ecommerce, mass market, department stores, pharmacies, perfumeries, hair salons, branded and travel retail), in 2025 the Group generated sales amounting to 44.05 billion euros. With 22 research centers across 9 regional hubs around the world and a dedicated Research and Innovation team of over 4,000 scientists and more than 8,000 Digital, Tech and Data talents, L’Oréal is focused on inventing the future of beauty and becoming a Beauty Tech powerhouse.

In 2025, L’Oréal has been named the most innovative company in Europe by Fortune magazine, out of 300 companies, in a ranking spanning 21 countries and 16 industries in Europe.

More information on https://www.loreal.com/en/mediaroom

Contacts at L’Oréal

Individual shareholders Mrs. Angélique FRUCHTENREICH Phone: +33.(0)1.47.56.45.35 Angelique.fruchtenreich@loreal.com

Financial analysts and institutional investors Mrs. Eva Quiroga Phone:+33.(0)7.88.14.22.65 eva.quiroga@loreal.com

For more information, please contact your bank, broker or financial institution (I.S.I.N. code: FR0000120321), and consult your usual newspapers, the Internet site for shareholders and investors, www.loreal-finance.com or the L’Oréal Finance app, alternatively, call +33 1 40 14 80 50.
“This document does not constitute an offer to sell, or a solicitation of an offer to buy, L’Oréal shares. If you wish to obtain more comprehensive information about L’Oréal, please refer to the public documents registered in France with the Autorités des Marchés Financiers [which are also available in English on our Internet site: www.loreal-finance.com].
This document may contain some forward-looking statements. Although the Company considers that these statements are based on reasonable hypotheses at the date of publication of this release, they are by their nature subject to risks and uncertainties which could cause actual results to differ materially from those indicated or projected in these statements.”

Attachment

• Reporting at 30 September 2026

French limited company (Société anonyme)
with registered capital of 106,529,962.80 euros
Registered office: 14, rue Royale, 75008 Paris
632 012 100 R.C.S. Paris
Legal Entity Identifier: 529900JI1GG6F7RKVI53

Disclosure of total number of voting rights and number of shares
in the capital at September 30, 2026

Pursuant to article L-233-8 II of the French “Code de Commerce” and
223-16 of the AMF’s General Regulations:

Total number of shares	532,649,827
Number of real voting rights (excluding treasury shares)	532,649,827
Theoretical number of voting rights (including treasury shares*) (*) pursuant to article 223-11 of the AMF’s General Regulations	532,649,827

About L’Oréal

For over 115 years, L’Oréal, the world’s leading beauty player, has devoted itself to one thing only: fulfilling the beauty aspirations of consumers around the world. Our purpose, to create the beauty that moves the world, defines our approach to beauty as essential, inclusive, ethical, generous and committed to social and environmental sustainability. With our broad portfolio of 40 international brands and ambitious sustainability commitments in our L’Oréal for the Future programme, we offer each and every person around the world the best in terms of quality, efficacy, safety, sincerity and responsibility, while celebrating beauty in its infinite plurality.

With more than 95,000 committed employees, a balanced geographical footprint and sales across all distribution networks (ecommerce, mass market, department stores, pharmacies, perfumeries, hair salons, branded and travel retail), in 2025 the Group generated sales amounting to 44.05 billion euros. With 22 research centers across 9 regional hubs around the world and a dedicated Research and Innovation team of over 4,000 scientists and more than 8,000 Digital, Tech and Data talents, L’Oréal is focused on inventing the future of beauty and becoming a Beauty Tech powerhouse.

In 2025, L’Oréal has been named the most innovative company in Europe by Fortune magazine, out of 300 companies, in a ranking spanning 21 countries and 16 industries in Europe.

More information on https://www.loreal.com/en/mediaroom

Contacts at L’Oréal

Individual shareholders Mrs. Angélique FRUCHTENREICH Phone: +33.(0)1.47.56.45.35 Angelique.fruchtenreich@loreal.com

Financial analysts and institutional investors Mrs. Eva Quiroga Phone:+33.(0)7.88.14.22.65 eva.quiroga@loreal.com

For more information, please contact your bank, broker or financial institution (I.S.I.N. code: FR0000120321), and consult your usual newspapers, the Internet site for shareholders and investors, www.loreal-finance.com or the L’Oréal Finance app, alternatively, call +33 1 40 14 80 50.
“This document does not constitute an offer to sell, or a solicitation of an offer to buy, L’Oréal shares. If you wish to obtain more comprehensive information about L’Oréal, please refer to the public documents registered in France with the Autorités des Marchés Financiers [which are also available in English on our Internet site: www.loreal-finance.com].
This document may contain some forward-looking statements. Although the Company considers that these statements are based on reasonable hypotheses at the date of publication of this release, they are by their nature subject to risks and uncertainties which could cause actual results to differ materially from those indicated or projected in these statements.”

Attachment

• Reporting at 30 September 2026

Bid date, 2026-10-06
Auction date	2026-10-06
Settlement date	2026-10-07
Maturity Date	2026-10-14
Nominal amount	471 billion SEK
Interest rate	1.75 %
Bid times	09.30-10.00 (CET/CEST) on the Bid date
Bids are made to phone number	08-696 69 70
Confirmation of bids to e-mail	rbcert@riksbank.se
The lowest accepted bid volume	1 million SEK
The highest accepted bid volume	471 billion SEK
Allocation Time	10.15 (CET/CEST) on the Bid date
Projected minimum liquidity surplus during the term	471 billion SEK
Expected excess liquidity at full allotment	0 billion SEK

Stockholm, 2026-10-06

Bid date, 2026-10-06
Auction date	2026-10-06
Settlement date	2026-10-07
Maturity Date	2026-10-14
Nominal amount	471 billion SEK
Interest rate	1.75 %
Bid times	09.30-10.00 (CET/CEST) on the Bid date
Bids are made to phone number	08-696 69 70
Confirmation of bids to e-mail	rbcert@riksbank.se
The lowest accepted bid volume	1 million SEK
The highest accepted bid volume	471 billion SEK
Allocation Time	10.15 (CET/CEST) on the Bid date
Projected minimum liquidity surplus during the term	471 billion SEK
Expected excess liquidity at full allotment	0 billion SEK

Stockholm, 2026-10-06